Drugs For Neglected Diseases Initiative (Dndi) company information, Employees & Contact Information

Collaborative Synthesis for Neglected Diseases through the Open Synthesis Network: Structure–Activity Relationships of Arylaminopyrazoles as Chagas Disease Treatments ACS Publications

AN2 Therapeutics and DNDi Collaborate on Clinical Development of Promising New Oral Compound to Treat Chronic Chagas Disease Yahoo Finance

IRD, DNDi, Institut Pasteur de Guinée and the Institut Pasteur welcome the WHO validation for the elimination of sleeping sickness in Guinea Institut Pasteur

Identification of Substituted 4-Aminocinnolines as Broad-Spectrum Antiparasitic Agents ACS Publications

Africa: Six African Nations Commit to Eliminate Deadly Neglected Disease Visceral Leishmaniasis allAfrica.com

Promising patient-friendly oral drug against visceral leishmaniasis enters Phase II clinical trial in Ethiopia World Health Organization (WHO)

Intersectoral partnerships, a necessary path to overcome the challenges presented by Chagas disease Frontiers

Early assessment of antibodies decline in Chagas patients following treatment using a serological multiplex immunoassay Nature

The pipeline for drugs for control and elimination of neglected tropical diseases: 1. Anti-infective drugs for regulatory registration Parasites & Vectors

Efficacy and safety of acoziborole in patients with human African trypanosomiasis caused by Trypanosoma brucei gambiense: a multicentre, open-label, single-arm, phase 2/3 trial The Lancet

Chemoinformatics Strategies for Leishmaniasis Drug Discovery Frontiers

Antibiotic-resistant gonorrhoea on the rise, new drugs needed World Health Organization (WHO)

Effectiveness and safety of fexinidazole for gambiense human African trypanosomiasis and exploration of adherence in outpatients: a phase 3b, prospective, open-label, non-randomised, cohort study The Lancet

Editorial: Drug discovery for emerging and neglected tropical diseases: advances, challenges and perspectives Frontiers

Practical Synthesis of 6-Amino-1-hydroxy-2,1-benzoxaborolane: A Key Intermediate of DNDI-6148 ACS Publications

Approved drugs successfully repurposed against Leishmania based on machine learning predictions Frontiers

Preclinical data do not support the use of amiodarone or dronedarone as antiparasitic drugs for Chagas disease at the approved human dosing regimen Frontiers

Clinical trials for Chagas disease: etiological and pathophysiological treatment Frontiers

Combination With Tomatidine Improves the Potency of Posaconazole Against Trypanosoma cruzi Frontiers

Next-Generation Approaches Needed to Tackle Antimicrobial Resistance for the Development of Novel Therapies Against the Deadly Pathogens Frontiers

Human African Trypanosomiasis (sleeping sickness): Current knowledge and future challenges Frontiers

Neglected Diseases Are Fierce, But So Is Monique Wasunna Global Health NOW

Changes in lipid abundance are associated with disease progression and treatment response in chronic Trypanosoma cruzi infection Parasites & Vectors

Barbituric Acid Derivatives as Covalent Inhibitors of Leishmania braziliensis Dihydroorotate Dehydrogenase ACS Publications

Novel Amino-pyrazole Ureas with Potent In Vitro and In Vivo Antileishmanial Activity ACS Publications

DNDi: “Bench-To-Bedside” Approach Needed For Drug & Vaccine Response To Global Health Crises Health Policy Watch

First Step for a Dreadful Disease: Get on the List Global Health NOW

RES-Seq—a barcoded library of drug-resistant Leishmania donovani allowing rapid assessment of cross-resistance and relative fitness ASM Journals

Importance of Raising Awareness of Chagas Disease News-Medical

Identification of potent inhibitors of Leishmania donovani and Leishmania infantum chagasi , the causative agents of Old and New World visceral leishmaniasis Nature

Nitroheterocyclic drugs cure experimental Trypanosoma cruzi infections more effectively in the chronic stage than in the acute stage Nature

R&D cost estimates - MSF response to Tufts CSDD study on cost to develop a new drug MSF Access

First large-scale survey of Chagas disease in the United States confirms that the 'silent killer' is a major public health challenge for the country EurekAlert!

Timeline: Innovation in action Doctors Without Borders

Eliminating visceral leishmaniasis in South Asia: the road ahead The BMJ

Social Non-profit Bioentrepreneurship: Current Status and Future Impact on Global Health Frontiers

Challenges and Opportunities for Drug Discovery in Developing Countries: The Example of Cutaneous Leishmaniasis ACS Publications

Pfizer attempts to mislead public over research and development ‘facts’ with Tube ads MSF Access

Paving the way for affordable and equitable liposomal amphotericin B access worldwide The Lancet

Drugs for neglected tropical diseases: availability of age-appropriate oral formulations for young children Parasites & Vectors

About the Pandemic Response Box Medicines for Malaria Venture

Chagas disease: pushing through the pipeline Nature

Antiparasitic Drugs in the United States—Two Roads to High Prices Frontiers

Screening strategies to identify new chemical diversity for drug development to treat kinetoplastid infections Cambridge University Press & Assessment

Enhancement of dissolution rate through eutectic mixture and solid solution of posaconazole and benznidazole ScienceDirect.com

Repurposing as a strategy for the discovery of new anti-leishmanials: the-state-of-the-art Cambridge University Press & Assessment

Drug Discovery for Neglected Diseases: Molecular Target-Based and Phenotypic Approaches ACS Publications

Leveraging biotech's drug discovery expertise for neglected diseases Nature

U.S. FDA Approves Chemo Group's Benznidazole to Treat Children with Chagas Disease PR Newswire UK

DNDi Taps Pfizer Compound Library Chemical & Engineering News